GHK-Cu
Naturally occurring copper chelated tripeptide (glycyl-L-histidyl-L-lysine copper complex). Extensively studied and approved as a cosmetic skincare ingredient (INCI: Copper Tripeptide-1). Systemic injectable pharmaceutical formulations are NOT FDA-approved.
60-Second Scientific Briefing
GHK-Cu (Copper Tripeptide-1) is a naturally occurring tripeptide-copper complex identified in human plasma. Widely utilized as a topical cosmetic ingredient for skin appearance and hair follicle conditioning. Extensively studied in gene expression models for tissue remodeling, but it is NOT an FDA-approved prescription drug.
What is GHK-Cu?
Pharmacological Classification & Molecular IdentityNaturally occurring copper chelate tripeptide with high affinity for Cu2+ ions, identified in human plasma, saliva, and urine.
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingBiological pathway and target receptor binding mechanism.
Receptor Selectivity: Modulates expression of collagen and elastin genes, regulates matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs), and exhibits anti-inflammatory antioxidant properties.
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsCosmetic ingredient (INCI: Copper Tripeptide-1). NOT approved as an injectable drug or prescription therapeutic by the US FDA.
GHK-Cu is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesSupported by extensive in vitro cell culture and small topical dermatological studies; lacks large-scale randomized double-blind Phase 3 drug registration trials.
Clinical Evidence
Supported by extensive in vitro cell culture and small topical dermatological studies; lacks large-scale randomized double-blind Phase 3 drug registration trials.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesTopical cosmetic use is generally well tolerated with occasional localized dermatitis. Systemic injectable toxicology and heavy metal copper accumulation risks require medical caution.
Potential systemic copper toxicity or mineral displacement if administered via unapproved injectable routes.
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNOT ESTABLISHED as an injectable drug. Cosmetic concentrations typically range from 0.05% to 2.0% in topical creams and serums.
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Naturally occurring copper chelate tripeptide with high affinity for Cu2+ ions, identified in human plasma, saliva, and urine.
- Targets & Selectivity: Modulates expression of collagen and elastin genes, regulates matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs), and exhibits anti-inflammatory antioxidant properties.
- Supported by extensive in vitro cell culture and small topical dermatological studies; lacks large-scale randomized double-blind Phase 3 drug registration trials.
- Safety considerations: Topical cosmetic use is generally well tolerated with occasional localized dermatitis. Systemic injectable toxicology and heavy metal copper accumulation risks require medical caution.
? Unknown / Under Ongoing Investigation
- Potential systemic copper toxicity or mineral displacement if administered via unapproved injectable routes.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysGHK-Cu is classified as a Copper Peptide Chelate Complex. Molecular structure: Naturally occurring copper chelate tripeptide with high affinity for Cu2+ ions, identified in human plasma, saliva, and urine..
Pharmacological classification and molecular integrity are documented in verified regulatory and scientific literature.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
GHK-Cu exerts biological activity via Modulates expression of collagen and elastin genes, regulates matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs), and exhibits anti-inflammatory antioxidant properties..
Receptor binding affinity and selectivity dictate the physiological response observed in laboratory and clinical trials.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Regulatory status: Cosmetic ingredient (INCI: Copper Tripeptide-1). NOT approved as an injectable drug or prescription therapeutic by the US FDA.
Investigational and research-only compounds cannot be legally distributed or marketed as prescription drugs.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Clinical evaluation status: Supported by extensive in vitro cell culture and small topical dermatological studies; lacks large-scale randomized double-blind Phase 3 drug registration trials.
Clinical trial readouts and systematic analyses establish the boundary between demonstrated findings and experimental hypotheses.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Reported safety profile: Topical cosmetic use is generally well tolerated with occasional localized dermatitis. Systemic injectable toxicology and heavy metal copper accumulation risks require medical caution.
Adverse reaction monitoring and contraindications are critical parameters in pharmacological risk-benefit evaluation.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Key scientific uncertainties: Potential systemic copper toxicity or mineral displacement if administered via unapproved injectable routes.
Egypt Peptides enforces strict transparency regarding scientific limitations and gaps in longitudinal clinical data.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
NOT ESTABLISHED as an injectable drug. Cosmetic concentrations typically range from 0.05% to 2.0% in topical creams and serums.
Under medical governance mandates, clinical study dosages represent strictly controlled experimental parameters and must never be interpreted as individual therapeutic advice.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Storage status: NOT ESTABLISHED for pharmaceutical injectable distribution. Topical products store at room temperature away from excessive heat and direct sunlight.
Peptide integrity degrades rapidly when exposed to elevated temperatures, repeated freeze-thaw cycles, or direct UV light exposure.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Yes. Unapproved pharmacological substances are strictly prohibited at all times in competitive sports under WADA Category S0 (Non-approved substances) or Category S2.
Athletes subject to drug testing face strict liability and multi-year competition bans upon detection of prohibited peptides or their metabolites.
- FDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) (U.S. Food and Drug Administration, 2023-09-29)
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Egypt Peptides provides peer-reviewed scientific reference monographs for research documentation. We strictly prohibit individual medical consultations, reconstitution guides, stacking recipes, or off-label use instructions.
All scientific claims must link to verified authoritative sources (FDA, PubMed, ClinicalTrials.gov) with zero tolerance for ungrounded marketing claims.
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018-07-07)
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and peer-reviewed studiesFDA Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 2 Safety Evaluation) ↗
https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data ↗
https://doi.org/10.3390/ijms19071987